1. Home
  2. SLGL vs NOM Comparison

SLGL vs NOM Comparison

Compare SLGL & NOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLGL
  • NOM
  • Stock Information
  • Founded
  • SLGL 1997
  • NOM 1993
  • Country
  • SLGL Israel
  • NOM United States
  • Employees
  • SLGL N/A
  • NOM N/A
  • Industry
  • SLGL Biotechnology: Pharmaceutical Preparations
  • NOM Investment Managers
  • Sector
  • SLGL Health Care
  • NOM Finance
  • Exchange
  • SLGL Nasdaq
  • NOM Nasdaq
  • Market Cap
  • SLGL 21.1M
  • NOM 25.0M
  • IPO Year
  • SLGL 2018
  • NOM N/A
  • Fundamental
  • Price
  • SLGL $7.24
  • NOM $10.78
  • Analyst Decision
  • SLGL Buy
  • NOM
  • Analyst Count
  • SLGL 1
  • NOM 0
  • Target Price
  • SLGL $40.00
  • NOM N/A
  • AVG Volume (30 Days)
  • SLGL 13.2K
  • NOM 6.9K
  • Earning Date
  • SLGL 05-23-2025
  • NOM 01-01-0001
  • Dividend Yield
  • SLGL N/A
  • NOM 3.39%
  • EPS Growth
  • SLGL N/A
  • NOM N/A
  • EPS
  • SLGL N/A
  • NOM N/A
  • Revenue
  • SLGL $12,103,000.00
  • NOM N/A
  • Revenue This Year
  • SLGL N/A
  • NOM N/A
  • Revenue Next Year
  • SLGL $31.17
  • NOM N/A
  • P/E Ratio
  • SLGL N/A
  • NOM N/A
  • Revenue Growth
  • SLGL 603.66
  • NOM N/A
  • 52 Week Low
  • SLGL $3.34
  • NOM $8.52
  • 52 Week High
  • SLGL $16.50
  • NOM $10.48
  • Technical
  • Relative Strength Index (RSI)
  • SLGL 50.26
  • NOM 56.60
  • Support Level
  • SLGL $7.15
  • NOM $10.40
  • Resistance Level
  • SLGL $7.45
  • NOM $10.89
  • Average True Range (ATR)
  • SLGL 0.32
  • NOM 0.13
  • MACD
  • SLGL -0.10
  • NOM -0.01
  • Stochastic Oscillator
  • SLGL 31.36
  • NOM 80.00

About SLGL Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.

About NOM Nuveen Missouri Quality Municipal Income Fund

Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.

Share on Social Networks: